October 2024

SIGN UP FOR OUR NEWSLETTER

We loved hearing the story of Engage Bio in a Founders at Work seminar generously sponsored by our longtime partners at Sartorius who have been working to support Engage’s nucleic acid purification work. Engage Bio is developing a new class of non-viral DNA medicines that are non-immunogenic, produce high levels of durable expression, and can be precisely tuned for cell or tissue specificity. Engage has been part of the 930 Brittan community since early 2022, and co-founder Will Olsen acknowledged how helpful their neighboring startup residents have been in supporting their work and lending their team reagents, equipment, and advice.


As Engage Bio charts its path to becoming a major force in genetic medicine, we take immense pride in having played a role in their early success story.

THE LATEST

SEE WHAT’S HAPPENING

MEET OUR NEWEST RESIDENTS

Published On: October 3rd, 2024Categories: Newsletters 2024
Feel free to share!